Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Invasive ductal carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44365   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Invasive ductal carcinoma. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2008-006161-84 Sponsor Protocol Number: Version 2.1 Start Date*: 2009-06-17
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: ARTiST - Aromasin Randomised Trial +/- Sutent as neoadjuvant Therapy for post-menopausal women with breast cancer.
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021944 Infiltrating ductal breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012853-39 Sponsor Protocol Number: Getna7/ CJP 1.0 Start Date*: 2009-09-23
    Sponsor Name:Centre Jean Perrin
    Full Title: Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study.
    Medical condition: RH- and Her2- operable breast cancer, in neoadjuvant situation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022882 Invasive ductal breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002371-13 Sponsor Protocol Number: TENEO Start Date*: 2007-11-06
    Sponsor Name:Centre Jean Perrin
    Full Title: A Pilot Phase II combination study of Taxotere (Docetaxel) and Erbitux (Cetuximab) as a NEOadjuvant therapy in patients with “triple-negative” (HR and Her2 negative) operable breast cancer. TENEO S...
    Medical condition: Cancer du sein opérable RH- et Her2-, en situation néoadjuvante
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022882 Invasive ductal breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003992-35 Sponsor Protocol Number: MREC02/8/71 Start Date*: 2009-12-16
    Sponsor Name:Queen Mary University of London
    Full Title: International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in situ.
    Medical condition: Ductal carcinoma in situ
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10013806 Ductal carcinoma in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004430-26 Sponsor Protocol Number: 010207QM Start Date*: 2015-06-08
    Sponsor Name:Queen Mary University of London
    Full Title: FEASIBILITY of IBIS 3. An International Breast Intervention Study investigating Prevention Of Late Recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment
    Medical condition: Late recurrence of hormone receptor positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021944 Infiltrating ductal breast cancer LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071113 Node-positive breast cancer LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022882 Invasive ductal breast cancer LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000553-23 Sponsor Protocol Number: GBG66 Start Date*: 2011-09-29
    Sponsor Name:German Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP)
    Full Title: A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer
    Medical condition: patients with triple-negative breast cancer, patients with HER2-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10021976 Inflammatory breast cancer stage IV LLT
    14.1 100000004864 10063104 Tubular breast cancer stage II LLT
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    14.1 100000004864 10022882 Invasive ductal breast cancer LLT
    14.1 100000004864 10028061 Mucinous breast cancer stage II LLT
    14.1 100000004864 10006188 Breast cancer female NOS LLT
    14.1 100000004864 10063105 Tubular breast cancer stage III LLT
    14.1 100000004864 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001943-21 Sponsor Protocol Number: IFG-08-2019 Start Date*: 2021-05-14
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: NeoOn – Neoadjuvant treatment of Ontruzant® (SB3) in patients with HER2-positive early breast cancer: An open-label, multicenter, phase IV study
    Medical condition: Female patients with early HER2positive breast cancer, neoadjuvantly treated.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006188 Breast cancer female NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021944 Infiltrating ductal breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006194 Breast cancer NOS stage I LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006195 Breast cancer NOS stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006196 Breast cancer NOS stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021974 Inflammatory breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014619-11 Sponsor Protocol Number: Kotoe_01 Start Date*: 2009-10-09
    Sponsor Name:Pirkanmaan sairaanhoitopiiri
    Full Title: The effect of dexmedetomidine on reactivity of a propofol-anaesthetized patient
    Medical condition: Surgical patients scheduled for elective surgery under general anaesthesia. Otherwise in stable medical condition (ASA status 1 or 2).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10023696 Laparotomy LLT
    12.0 10023697 Laparotomy & drainage LLT
    12.0 10051777 Staging laparotomy LLT
    12.0 10053361 Explorative laparotomy LLT
    12.0 10023693 Laparoscopy LLT
    12.0 10069054 Pelvic laparoscopy LLT
    12.0 10006187 Breast cancer LLT
    12.0 10006188 Breast cancer female NOS LLT
    12.0 10006193 Breast cancer NOS recurrent LLT
    12.0 10006198 Breast cancer recurrent LLT
    12.0 10006203 Breast cancer stage unspecified LLT
    12.0 10021944 Infiltrating ductal breast cancer LLT
    12.0 10021974 Inflammatory breast cancer LLT
    12.0 10022779 Intraductal breast cancer (in situ) LLT
    12.0 10025025 Lumpectomy (breast cancer) LLT
    12.0 10027475 Metastatic breast cancer LLT
    12.0 10028058 Mucinous breast cancer LLT
    12.0 10048406 Breast cancer aggravated LLT
    12.0 10055113 Breast cancer metastatic LLT
    12.0 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003575-18 Sponsor Protocol Number: ICO-2020-06 Start Date*: 2020-12-08
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
    Medical condition: Patients with extensive ductal carcinoma in situ with an indication for total mastectomy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006189 Breast cancer in situ PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007740-10 Sponsor Protocol Number: TAM-01 Start Date*: 2008-01-30
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA
    Full Title: Randomized placebo-controlled phase III trial of low-dose tamoxifen women whit IntraEphitelial Neoplasia(IEN)
    Medical condition: chemoprevention of breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001128-11 Sponsor Protocol Number: BO20289 Start Date*: 2007-12-14
    Sponsor Name:F. Hoffmann-La Roche Ltd, Pharmaceuticals Divison, PDR
    Full Title: An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.
    Medical condition: Early primary invasive adenocarcinoma of the breast (triple negative and/or basel-like phenotype)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006291 Breast neoplasms malignant and unspecified (incl nipple) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) AT (Completed) NL (Completed) BE (Completed) CZ (Completed) GR (Completed) FI (Completed) DE (Completed) IT (Completed) ES (Completed) PT (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003047-24 Sponsor Protocol Number: CA163-100 Start Date*: 2007-05-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women with Early Stage Breast Cancer Not Overexpressin...
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed) GB (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002018-37 Sponsor Protocol Number: BO27938 Start Date*: 2013-04-09
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BRE...
    Medical condition: HER2-positive primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) IE (Prematurely Ended) ES (Ongoing) GR (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007345-31 Sponsor Protocol Number: 3144A2-3004-WW Start Date*: 2009-08-05
    Sponsor Name:Puma Biotechnology, Inc
    Full Title: A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.
    Medical condition: Her2 overexpressed, early stage breast cancer (adjuvant treatment stage)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10006173 Breast adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) DE (Completed) IT (Completed) SK (Completed) CZ (Completed) ES (Completed) BE (Completed) GB (Completed) LT (Completed) NL (Completed) FR (Completed) DK (Completed) SE (Completed) GR (Completed) MT (Completed) BG (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005186-10 Sponsor Protocol Number: EGF105485 Start Date*: 2006-09-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer
    Medical condition: Women with early-stage ErbB2-overexpressing breast cancer. Eligible women must have had an initial diagnosis of histologically or cytologically confirmed invasive breast cancer (Stage I through St...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) LT (Completed) ES (Completed) BE (Completed) DK (Completed) LV (Completed) GR (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017485-23 Sponsor Protocol Number: EORTC90091-10093 Start Date*: 2013-04-24
    Sponsor Name:EORTC
    Full Title: TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial)
    Medical condition: HER2-Negative Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) GB (Completed) DE (Completed) GR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004902-82 Sponsor Protocol Number: BO28407 Start Date*: 2014-01-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCL...
    Medical condition: HER2-positive operable primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) CZ (Completed) ES (Temporarily Halted) NO (Completed) BE (Prematurely Ended) SE (Prematurely Ended) PL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002162-21 Sponsor Protocol Number: JECF-VITD-2011-01 Start Date*: 2012-04-24
    Sponsor Name:José Esteban Castelao Fernández
    Full Title: A phase II randomized, prospective, multicenter, placebo-controlled clinical trial to evaluate the chemopreventive effect of vitamin D in women at high risk of breast cancer.
    Medical condition: Women at high risk of developing breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000134-34 Sponsor Protocol Number: TEAM(B115UCS2019) Start Date*: 2021-05-24
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, window of opportunity presurgical trial.
    Medical condition: Luminal (ER+ve and/or PgR+ve >=1%) invasive breast cancer not candidate to neo - adjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006259-12 Sponsor Protocol Number: 1814 Start Date*: 2012-09-03
    Sponsor Name:Jules Bordet Institute
    Full Title: Phase II study on prospective evaluating the quantification of total choline by magnetic resonance spectroscopy (MRS) in breast tumours as an early predictive marker of neoadjuvant chemotherapy res...
    Medical condition: Early breast cancer requiring neoadjuvant chimiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Dec 08 09:19:10 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA